The Q1 results were a testimony to the abilities of the management. While the employee cost had been a one off high expense which should get streamlined accompanied by the depreciation of the new facility, the prospects for the year seem to be rosy.
CDMO business consistently hitting above 100 Cr mark
The injectibles facility on track to add to the business margins
The trade generic business poised to be a strong business
Management that seems to be good capital allocator
2-3 years down the line the prospect of exports once they gain momentum with filings
One of the most important things is that the facilities are compliant with the strictest of Norms and in case some policy comes out, Windlas might become an indirect beneficiary.
Is one of the biggest holdings and have done transaction in last 30 days
| Subscribe To Our Free Newsletter |
